MorphoSys AG

NasdaqGS:MOR Stock Report

Market Cap: US$2.8b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Arkadius Pichota

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenure6.5yrs

Recent management updates

Recent updates

MorphoSys: Hold Rating Until The Novartis Deal Closes

May 01

Novartis And MorphoSys Are A Perfect Match

Feb 06

MorphoSys: Positive Pelabresib Data Finally Unlocking Upside

Jan 18

MorphoSys updates Q2 & FY22 guidance below prior provided levels

Jul 26

MorphoSys May Not Recover From Adventurous Constellation Buyout

May 04

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

Jan 28

Incyte and MorphoSys presents new three-year data for blood cancer therapy

Jun 04

MorphoSys reports Q1 results

May 05

MorphoSys AG appoints Sangamo 's Sung Lee as new CFO

Jan 06

MorphoSys AG (MOR) Investor Presentation - Slideshow

Dec 08

MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation

Nov 22

MorphoSys reports Q3 results

Nov 11

CEO

Arkadius Pichota

less than a year

Tenure

Mr. Arkadius Pichota, Ph D., MBA., is Chief Executive Officer of MorphoSys AG from June 2024. Mr. Pichota served as President, General Manager and Chairman of the Board of the Novartis subsidiary Navigate...

Leadership Team

NamePositionTenureCompensationOwnership
Charlotte Lohmann
Chief Legal and Human Resources Officer & Member of Management Board4.6yrs€1.10m0.0036%
$ 99.7k
Arkadius Pichota
Chief Executive Officerless than a yearno datano data
Lukas Gilgen
Chief Financial Officerless than a yearno datano data
Tim Demuth
Chief Research & Development Officer1.8yrsno datano data
Klaus De Wall
Head of Accounting & Taxno datano datano data
Margit Urban
Head of Discovery Alliances & Technologiesno datano datano data
Julia Neugebauer
Head of Investor Relationsno datano datano data
Barbara Krebs-Pohl
Chief Business Officerno datano datano data
Günter Wellnhofer
Head of Technical Operationsno datano datano data
Harald Watzka
Head of Alliance Managementno datano datano data
Yen Ching Chua
Head of Clinical Operationsno datano datano data
Kathrin Tissot
Head of Business Teamno datano datano data

1.0yrs

Average Tenure

Experienced Management: MOR's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Bruce Cheson
Member of Scientific Advisory Board7.9yrsno datano data
Gunther Adolf
Member of Scientific Advisory Board7.9yrsno datano data
Sergio Quezada
Member of Scientific Advisory Board7.9yrsno datano data
Raymond Sweet
Member of Scientific Advisory Board7.9yrsno datano data
Sharon Curran
Independent Member of Supervisory Board5.2yrs€92.60kno data
Heinrich V. Moisa
Chairman of the Supervisory Boardless than a yearno datano data
Silke Mainka
Member of the Supervisory Boardless than a yearno datano data
Romain Lege
Deputy Chairman of the Supervisory Boardless than a yearno datano data

6.5yrs

Average Tenure

51yo

Average Age

Experienced Board: MOR's board of directors are considered experienced (6.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/05 22:34
End of Day Share Price 2024/08/05 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MorphoSys AG is covered by 35 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Olav ZilianBaader Helvea Equity Research
Brian BalchinBarclays
Rosie TurnerBarclays